Search
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalIt is considered as a performance enhancing drug thus is prohibited from use in sports.
Deferitazole
go.drugbank.com/drugs/DB13120InvestigationalDeferitazole is an iron chelator. … It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red
Nigella sativa oil
go.drugbank.com/drugs/DB28165InvestigationalNigella Sativa Oil is under investigation in clinical trial NCT06823544 (A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis
Medical air
go.drugbank.com/drugs/DB09337ApprovedInvestigationalVet approvedMedical air is supplied by a special air compressor to patient care areas using clean outside air.
UM-171
go.drugbank.com/drugs/DB19449InvestigationalUM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]
SLx-4090
go.drugbank.com/drugs/DB05678InvestigationalSLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [L48216] Integrins implicated in cell migration into the intestinal tract included α2β2, α4β1, and α4β7; however, the selective activity of vedolizumab against α4β7 integrin has been thought to contribute
Products: ENTYVIO PenNeramexane
go.drugbank.com/drugs/DB04926InvestigationalNeramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.